Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment

Hao Xu; Ke-Ji Chen; Da-zhuo Shi; Xiao-chang Ma; Shu-zheng Lu; Jie-ming Mao

doi:10.1007/BF02934299

Your Location：

Home >

Browse articles >

Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment

Updated：2021-08-27

- Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment
- Chinese Journal of Integrative Medicine Vol. 8, Issue 3, Pages: 162-166(2002)
- Affiliations：
  
  1. Xiyuan Hospital, China Academy of TCM,Beijing
  2. The Third Hospital Affiliated to Peking University, Health Science Center,USA
  3. Anzhen Hospital Affiliated to Capital University of Medical Sciences,USA
- Author bio：
- Funds：
  
  National Ninth Five-Year Project (No. 96-906-06-01)
- DOI：10.1007/BF02934299
  CLC：
- Published：2002，
Scan for full text
Xu, H., Chen, Kj., Shi, Dz. et al. Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment., CJIM 8, 162–166 (2002). https://doi.org/10.1007/BF02934299

Hao Xu, Ke-Ji Chen, Da-zhuo Shi, et al. Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment. [J]. Chinese Journal of Integrative Medicine 8(3):162-166(2002)
Xu, H., Chen, Kj., Shi, Dz. et al. Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment., CJIM 8, 162–166 (2002). https://doi.org/10.1007/BF02934299 DOI：

Hao Xu, Ke-Ji Chen, Da-zhuo Shi, et al. Clinical study of xiongshao capsule in preventing restenosis after coronary interventional treatment. [J]. Chinese Journal of Integrative Medicine 8(3):162-166(2002) DOI： 10.1007/BF02934299.

摘要

To evaluate the effect of Xiongshao Capsule in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. The total of 108 coronary heart disease patients with successful coronary angioplasty or/and stenting were randomly divided into the control group (55 cases

routine treatment) and the XS group (53 cases

routine treatment combined with XS). The recurrence of angina

clinical end-point events

changing of blood-stasis syndrome score (BSSS) and coronary angiography within 6 month after coronary angioplasty or/and stenting were observed. Follow-up angiography was performed in 42 patients including 18 cases in the XS group (restenosis was observed in 7 patients) and 24 cases in the control group (restenosis was observed in 17 patients)

there was significant difference between the occurrence of restenosis in XS and that in control group (P < 0.05). The occurrence of clinical end-point events (death

nonfatal target lesion myocardial infarction

coronary artery bypass graft surgery

or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%)(P <0.05). The recurrent angina was observed in 13 cases in the XS group

there was significant difference as compared with 27 cases in the control group (P <0.05). There was also remarkable significance for the difference of base-line and follow-up BSSS between groups (P < 0. 01). Logistic multivariate stepwise regress analysis and multivariate regress analysis of the related factors with restenosis confirmed by coronary angiography showed that

the base-line BSSS and the difference of base-line and follow-up BSSS were important influencing factors on the occurrence of restenosis after interventional treatment (P < 0.05). XS could markedly reduce the occurrence of angiographic restenosis

clinical end-point events and recurrent angina

improve condition of blood-stasis after coronary angioplasty or/and stenting. The severity of blood-stasis syndrome was an important influencing factor on the occurrence of restenosis. It still needs to be further demonstrated by large-scale

double-blinded

randomized and controlled study.

Abstract

routine treatment) and the XS group (53 cases

routine treatment combined with XS). The recurrence of angina

clinical end-point events

there was significant difference between the occurrence of restenosis in XS and that in control group (P < 0.05). The occurrence of clinical end-point events (death

nonfatal target lesion myocardial infarction

coronary artery bypass graft surgery

or repeat target-vessel angioplasty) in the XS group (18.8%) was significantly lower than that in the control group (40%)(P <0.05). The recurrent angina was observed in 13 cases in the XS group

clinical end-point events and recurrent angina

double-blinded

randomized and controlled study.

关键词

Xiongshao capsuleangioplastystentrestenosis

Keywords

Xiongshao capsuleangioplastystentrestenosis

references

Hong MK, Mehran R, Mintz GS, et al. Restenosis after coronary angioplasty. Current Problem in Cardiology 1997; 22(l):7–36.

Shi DZ, Xu FQ, Ma XC, et al. The experimental study of Xue Guan Tong on preventing restenosis after percutaneous transluminal angioplasty. Chin J Integr Med 1995; 1 (4):284–287.

Shi DZ, LI J, Ma XC, et al. Clinical observation of concentrated Xufu Zhuyu Pill on preventing restenosis after percutaneous transluminal coronary angioplasty in patients of coronary heart disease. Chin J of TCM 1997;38(1):27–29.

Xu H, Shi DZ, Chen KJ, et al. Effect of Xiongshao capsule on vascular remodeling in porcine coronary balloon injury model. Chin J Integr Med 2001 ;21(8): 591–594.

Xu H, Shi DZ, Chen KJ, et al. Effect of XS0601 on apoptosis and gene expression of p53 and bcl-2 in neointima of porcine coronary artery after balloon injury. Chin J In-terventional Cardiology 2001;9(3): 152–154.

Xu H, Shi DZ, Chen KJ, et al. Effect of Xiongshao capsule on proliferation and apoptosis of vascular smooth muscle cells in rabbits observed by serologic pharmacological method. Chin J Integr Med 2000;20(10): 757–760.

Chen HZ edited. Internal Medicine. 1st Edition. Beijing: The People’s Health Publishing House, 1995:263–264.

The Speciality Committee of Promoting Blood Circulation and Removing Blood-Stasis of Chinese Association of Integrative Western and Chinese Medicine. The Diagnostic Criteria of Blood-stasis Syndrome. Chin J Integr Med 1987; 7 (3):129.

Wang J. Study on diagnostic criteria of blood-stasis syndrome. Research and Clinical Application of Promoting Blood Circulation and Removing Blood-Stasis. 1st Edition. Beijing: The United Publishing House of Beijing Medical University and China Union Medical University, 1993:7.

Chen ZJ edited. Clinical coronary heart disease. 1st edition. Beijing: Publishing House of People Military Surgeon, 1994: 345–351.

Yu B, Chen KJ, Mao JM, et al. Clinical study of concentrated Xuefu Zhuyu Pill on preventing restenosis after coronary stenting in patients of coronary heart disease. Chin J Integr Med 1998; 18(10):585–589.

FULL TEXT LINK

More>

Views

368

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effect of xiongshao capsule on vascular remodeling in porcine coronary balloon injury model

A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule (芎芍胶囊) in preventing restenosis after percutaneous coronary intervention: A subgroup analysis of senile patients

Long-term effect of stent coating with zedoary essential components on neointimal formation in the porcine coronary artery

Combined common femoral artery endarterectomy with superficial femoral artery stenting plus Shuxuening Injection (舒血宁注射液) infusion for chronic lower extremity ischemia: 3-year results

Xiongshao Capsule (芎芍胶囊) promotes angiogenesis of HUVEC via enhancing cell proliferation and up-regulating the expression of bFGF and VEGF

Related Author

No data

Related Institution

Division of Cardiovascular Diseases, Xiyuan Hospital, China Academy of TCM

Department of Experimental Surgery, Fuwai Cardiovascular Hospital, Chinese Academy of Medical Sciences

Xiyuan Hospital, China Academy of Chinese Medical Sciences

National Integrative Medicine Center for Cardiovascular Diseases, China-Japan Friendship Hospital

Beijing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰